Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Highly Accessed Research article

NF-κB targeting by way of IKK inhibition sensitizes lung cancer cells to adenovirus delivery of TRAIL

Cigdem Aydin1, Ahter D Sanlioglu1, Atil Bisgin2, Burcak Yoldas3, Levent Dertsiz4, Bahri Karacay5, Thomas S Griffith6 and Salih Sanlioglu2*

Author Affiliations

1 Department of Medical Biology and Genetics, Human Gene and Cell Therapy Center of Akdeniz University Hospitals and Clinics, Antalya, 07058, Turkiye

2 Department of Medical Genetics, Human Gene and Cell Therapy Center of Akdeniz University Hospitals and Clinics, Antalya, 07058, Turkiye

3 Human Gene and Cell Therapy Center of Akdeniz University Hospitals and Clinics, Antalya, 07058, Turkiye

4 Department of Thorasic Surgery, Akdeniz University Faculty of Medicine, Antalya, 07058, Turkiye

5 Department of Pediatrics and Gene Therapy Center, University of Iowa, Iowa City, IA, 52242, USA

6 Department of Urology and Gene Therapy Center, University of Iowa, Iowa City, IA, 52242, USA

For all author emails, please log on.

BMC Cancer 2010, 10:584  doi:10.1186/1471-2407-10-584

Published: 27 October 2010

Abstract

Background

Lung cancer causes the highest rate of cancer-related deaths both in men and women. As many current treatment modalities are inadequate in increasing patient survival, new therapeutic strategies are required. TNF-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis in tumor cells but not in normal cells, prompting its current evaluation in a number of clinical trials. The successful therapeutic employment of TRAIL is restricted by the fact that many tumor cells are resistant to TRAIL. The goal of the present study was to test a novel combinatorial gene therapy modality involving adenoviral delivery of TRAIL (Ad5hTRAIL) and IKK inhibition (AdIKKβKA) to overcome TRAIL resistance in lung cancer cells.

Methods

Fluorescent microscopy and flow cytometry were used to detect optimum doses of adenovirus vectors to transduce lung cancer cells. Cell viability was assessed via a live/dead cell viability assay. Luciferase assays were employed to monitor cellular NF-κB activity. Apoptosis was confirmed using Annexin V binding.

Results

Neither Ad5hTRAIL nor AdIKKβKA infection alone induced apoptosis in A549 lung cancer cells, but the combined use of Ad5hTRAIL and AdIKKβKA significantly increased the amount of A549 apoptosis. Luciferase assays demonstrated that both endogenous and TRAIL-induced NF-κB activity was down-regulated by AdIKKβKA expression.

Conclusions

Combination treatment with Ad5hTRAIL and AdIKKβKA induced significant apoptosis of TRAIL-resistant A549 cells, suggesting that dual gene therapy strategy involving exogenous TRAIL gene expression with concurrent IKK inhibition may be a promising novel gene therapy modality to treat lung cancer.